Lexeo Therapeutics, Inc. Common Stock (LXEO) is a Healthcare · Biotechnology company listed on NASDAQ. Price $4.15 (-0.72%), Market cap $0.40B, 52-week low–high $2.70 ~ $10.63.
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with
Financial statements, price targets, institutional (13F) holdings and related news for Lexeo Therapeutics, Inc. Common Stock are updated in real time on BlackAll Trade.
Lexeo Therapeutics, Inc. Common Stock trades at $4.15 (-0.72%). Real-time quotes and charts are available on BlackAll Trade.
Lexeo Therapeutics, Inc. Common Stock has a market cap of about $0.40B.
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AA